Great to see Prof. Anna Nowak present results of our international phase 3 #mesothelioma trial #DREAM3R today at #ESMO25 a really enjoyable academic trial collaboration between Thoracic Oncology Group of Australasia PrECOG

The PrE1702 #RealWorldData research study is evaluating how well osimertinib with or without chemotherapy works to control EGFR-positive #LungCancer in patients not participating in a clinical trial. Learn more: bit.ly/pre1702-study #LCSM #RWD #RWE

Congratulations to the early-career researchers selected to present at our annual Young Investigator Symposium!🩻🩺📈#EAOnc

The PrE1702 #RealWorldData research study is evaluating how well osimertinib with or without chemotherapy works to control EGFR-positive #LungCancer in patients not participating in a clinical trial. Learn more: bit.ly/pre1702-study #LCSM #RWD #RWE

.Jefferson Health is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study

DYK only 17% of US cancer trials are federally funded—yet they’re far more likely to study rare cancers, pediatric cancers, & multimodality treatments? Public funding = innovation where it’s needed most. More: bit.ly/47kYNME #Oncology #CancerResearch DrJoeUnger SWOG Cancer Research Network

The PrE1702 #RealWorldData research study is evaluating how well osimertinib with or without chemotherapy works to control EGFR-positive #LungCancer in patients not participating in a clinical trial. Learn more: bit.ly/pre1702-study #LCSM #RWD #RWE

Great work to ProHealth Care for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/4hyZUue #LCSM

After being diagnosed with #PancreaticCancer, Steven Merlin found hope through a #clinicaltrial. Now as an ECOG-ACRIN Cancer Research Group advocate, he shares his perspective on the benefits of clinical trials. Read his inspiring story: bit.ly/beatingtheodds… cc: Let's Win Pancreatic Cancer 💜, PanCAN, The Seena Magowitz Foundation

How well does osimertinib—with or without chemotherapy—work to control EGFR-positive #LungCancer in patients not participating in a clinical trial? The PrE1702 #RealWorldData research study aims to find out. More: bit.ly/pre1702-study #LCSM #RWD #RWE

Kudos to Virtua Health for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study

The PrE1702 #RealWorldData research study is evaluating how well osimertinib with or without chemotherapy works to control EGFR-positive #LungCancer in patients not participating in a clinical trial. Learn more: bit.ly/pre1702-study #LCSM #RWD #RWE

On #WorldPancreaticCancerDay 💜 we are shining a light on two ECOG-ACRIN Cancer Research Group clinical trials aiming to improve outcomes for patients with #PancreaticCancer & #PancreaticCysts - EA2185 and EA2192/APOLLO. Learn more here 👉 bit.ly/pancreaticf25 cc: Let's Win Pancreatic Cancer 💜, PanCAN, Kim Reiss Binder (Kim Reiss)

In honor of #LungCancer Awareness Month, learn about PrE0510! This #ClinicalTrial is a phase II study of platinum/​etoposide plus ivonescimab for extensive-stage small cell lung cancer (#SCLC). Click here for more 👉clinicaltrials.gov/study/NCT07057… cc: Taofeek K Owonikoko #LCAM #LCSM

.Stanford Cancer Institute is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study cc: Joel W. Neal, MD, PhD

Great work to Vanderbilt Health for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study cc: Christine Lovly, MD, PhD, FASCO

The PrE1702 #RealWorldData research study is evaluating how well osimertinib with or without chemotherapy works to control EGFR-positive #LungCancer in patients not participating in a clinical trial. Learn more: bit.ly/pre1702-study #LCSM #RWD #RWE

Guide to #ASH2025 | ECOG-ACRIN & PrECOG are set to reveal multiple blood cancer research discoveries at the 67th American Society for Hematology (ASH) Annual Meeting and Exposition, Dec 6-9, in Orlando ecog-acrin.org/guide-to-ash-2… ECOG-ACRIN Cancer Research Group PrECOG #ASH25 #E1910 #leukemia #lymphoma

How well does osimertinib—with or without chemotherapy—work to control EGFR-positive #LungCancer in patients not participating in a clinical trial? The PrE1702 #RealWorldData research study aims to find out. More: bit.ly/pre1702-study #LCSM #RWD #RWE

.Geisinger is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study